Vaccine and Clinical Trials

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally Bacterial co-infections are correlated with unfavorable outcomes in respiratory viral infections. Despite, microbiological and antibiotic data related to COVID-19 are skimpy, competent use of antibiotics in line with antibiotic stewardship (ABS) principles is guaranteed during the pandemic. Bacterial and fungal co-infections are subtle in COVID-19 patients and are mainly ubiquitous in critically ill patients. In addition, studies are needed to estimate the impact of antimicrobial therapy on therapeutic outcomes in COVID-19 patients to prevent antimicrobial overuse. A novel beta-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was consequently identified as the causative pathogen. Ordinarily, respiratory viral infections are a risk factor for bacterial co-infections, which then increase disease austerity and mortality. It has been established that sepsis and ventilator-associated pneumonia are frequently observed complications in COVID-19 patients.